Panacea Biotec Pharma Limited

Panacea Biotec Pharma Limited - pharma in New Delhi, Delhi, India. FY 2026 financials & compliance.
CIN U24299DL2019PLC347566 Incorporated 22 March 2019 ROC Delhi HQ New Delhi, Delhi, India
Active Public Limited Company pharma
Revenue · FY 2025
₹265.23 Cr
▲ 26% YoY
Net profit · FY 2025
₹16.94 Cr
Net margin 6.4%
EBITDA · FY 2025
₹37.16 Cr
EBITDA margin 14%
Authorised capital
₹60 Cr
Registered with MCA
Paid-up capital
₹10 Lakh
Issued & subscribed
Satisfied charges
₹1,618.44 Cr
No open charges
Company age
7 yrs
Est. 2019
Employees · EPFO
940
Provident fund records

About Panacea Biotec Pharma Limited

Data last updated:

Panacea Biotec Pharma Limited is a public limited company based in New Delhi, Delhi, India, a subsidiary of Panacea Biotec Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 22 March 2019 and has been in existence for over 7 years.

The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24299DL2019PLC347566. Its GSTIN is 07AAKCP4431B1ZQ (Delhi). The company holds 22 GST registrations, of which 21 are active.

The company has an authorised share capital of ₹60 Cr and a paid-up capital of ₹10 Lakh. It is led by directors including Rajesh Jain (Managing Director) and Ankesh Jain (Whole-Time Director).

Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at B – 1 Extension/A – 27 Mohan Co – Operative Industrial Estate Mathura Road, New Delhi, Delhi, India – 110044.

As per the financials filed for FY 2025, the company reported a revenue of ₹265.23 Cr, a growth of 26% compared to the previous year. For the same year it recorded a net profit of ₹16.94 Cr (net margin 6.4%) and EBITDA of ₹37.16 Cr (EBITDA margin 14%). Revenue has grown at a compounded annual rate (CAGR) of 13% over three years and 37% over five years.

The company has about 940 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Panacea Biotec. As per MCA filings, the company has satisfied charges of ₹1,618.44 Cr on record. Court records list 5 cases involving the company, including 1 filed by the company and 4 filed against it; 2 cases are pending. The company has 3 deals on record (2 debt financings, 1 acquisition), with disclosed funding of ₹808.43 Cr; the latest was in February 2022. Its 3 peer companies in the Healthcare industry (Formulations, Preventive Healthcare Supplements), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 1 smaller; the largest is Amn Life Science Private Limited with revenue of ₹273.11 Cr. The company has 34 MSME Form 1 returns on record between 2020 and 2024, listing 1,642 overdue payments to 181 micro and small suppliers.

For more details, the company can be reached via its website panaceabiotec.com.

Company details

CIN U24299DL2019PLC347566
Registration Number 347566
Incorporation Date 22 March 2019
ROC Delhi
Listing Status Unlisted
Company Status Active
Parent Company Panacea Biotec Limited

CIN history

Panacea Biotec Pharma has one previous CIN (Corporate Identification Number): U24299PB2019PLC068319. The current CIN is U24299DL2019PLC347566, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24299DL2019PLC347566Current
U24299PB2019PLC068319Previous

Contact details

Panacea Biotec Pharma Limited's registered office is in New Delhi, Delhi. Its website is panaceabiotec.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Social Media
  • Registered Address
    B – 1 Extension/A – 27 Mohan Co – Operative Industrial Estate Mathura Road, New Delhi, Delhi, India – 110044
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Panacea Biotec Pharma Limited, buy the company report.

Comprehensive company report
Panacea Biotec Pharma Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Panacea Biotec Pharma operates one associated brand: Panacea Biotec. Each brand links to its own profile.

BrandDescriptionWebsite
Developer of biosimilars, vaccines and natural productspanaceabiotec.com

Business activity

The main business activity of Panacea Biotec Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Panacea Biotec Pharma Limited, buy the company report.

Financials of Panacea Biotec Pharma Limited

FY 2025 filings available

Panacea Biotec Pharma Limited reported revenue of ₹265.23 Cr (up 26% YoY) for FY 2025.

Revenue · FY 2025
₹265.23 Cr ▲ 26%
Net profit · FY 2025
₹16.94 Cr margin 6.4%
EBITDA · FY 2025
₹37.16 Cr margin 14%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 26%
3 years · compounded
▼ 13%
5 years · compounded
▲ 37%
EBITDA CAGR growth
1 year
▲ 201%
3 years · compounded
▼ 2%
5 years · compounded
▲ 56%

Revenue has grown at a compounded annual rate (CAGR) of 37% over five years, including 26% growth in the latest year. EBITDA rose 201% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹265.23 Cr
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹37.16 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)₹16.94 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin14%
Net Profit Margin6.4%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Panacea Biotec Pharma Limited, buy the company report.

Board of directors of Panacea Biotec Pharma Limited

Panacea Biotec Pharma has 6 current directors and 11 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Ankesh JainWhole-Time Director22 Mar 20197 Years 7 MonthsCurrent
Rajesh JainDirector12 Nov 20242 Years 0 MonthsCurrent
Manjula UpadhyayDirector23 Jul 20215 Years 3 MonthsCurrent
Narotam Kumar JunejaWhole-Time Director01 Apr 20224 Years 7 MonthsCurrent
Rajesh JainManaging Director22 Mar 20197 Years 7 MonthsCurrent
Sanjay TrehanWhole-Time Director13 Feb 20251 Years 9 MonthsCurrent

Peer comparison

Panacea Biotec Pharma Limited is compared with the 3 companies closest to it by revenue in the Healthcare industry (Formulations, Preventive Healthcare Supplements), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Amn Life Science Private Limited₹273.11 Cr (FY 2025)42.0%Mumbai, Maharashtra, India
Selmar Lab Private Limited₹269.27 Cr (FY 2024)-14.0%Hyderabad, Telangana, India
Panacea Biotec Pharma Limitedthis company₹265.23 Cr (FY 2025)₹16.94 Cr6.4%26.0%940New Delhi, Delhi, India
Psychotropics India Limited₹261.89 Cr (FY 2025)-8.0%Faridabad, Haryana, India

To see the full peer comparison of Panacea Biotec Pharma Limited, buy the company report.

Auditor

Panacea Biotec Pharma Limited is audited by Suresh Surana & Associates LLP for the financial year 2025.

Auditor firmFinancial yearFirm registration number
Suresh Surana & Associates LLPFY 2025121750W/W100010

Shareholding

The shareholding of Panacea Biotec Pharma Limited is on record for 5 financial years, the latest being FY 2025, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2025FY 2024FY 2023FY 2022FY 2021
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Panacea Biotec Pharma Limited, buy the company report.

Charges & borrowings

Open charges
None
Satisfied charges
₹1,618.44 Cr
Breakdown by lending institutions
Others₹1,618.44 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
01 Feb 2020100332250Others₹754.44 CrSatisfied
06 Apr 2019100258765Others₹864 CrSatisfied

To see the full charge records of Panacea Biotec Pharma Limited, buy the company report.

Total charge records: 2 View all charges

Deals & funding

Panacea Biotec Pharma Limited has 3 deals on record (2 debt financings, 1 acquisition), with disclosed funding of ₹808.43 Cr; the latest was in February 2022.

Total deals
3
Debt financings
2
Acquisition
1
Disclosed funding
₹808.43 Cr

Deals on record (3 of 3)

WhenDealAmountParties
Feb 2022Acquisition₹1,807.65 CrBuyer: Mankind Pharma Limited
Seller: Panacea Biotec Pharma Limited
Oct 2020Debt financing₹96 CrInvestors: IndiaRF, Piramal Structured Finance
Feb 2020Debt financing₹712.43 CrInvestors: IndiaRF, Piramal Structured Finance

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Panacea Biotec Pharma Limited has 34 MSME Form 1 returns on record between 2020 and 2024, listing 1,642 overdue payments to 181 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 181)

SupplierAmount dueDue sinceReported on
an individual supplier
Acechem Global
Eco Energy Industries
an individual supplier
Arizona Automation & Controls

To see the full MSME payment records of Panacea Biotec Pharma Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Panacea Biotec Pharma Limited has a workforce of 940 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.

Employee count
940
Active EPFO establishments
1
Employee growth
8.3%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-27940
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20

To see the full employee and EPFO history of Panacea Biotec Pharma Limited, buy the company report.

GST

Panacea Biotec Pharma has 22 GST registrations: 21 active and 1 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
22
Active
21
Cancelled / inactive
1
GSTINStateStatusRegistered on
07AAKCP4431B1ZQDelhiActive16 Apr 2019
07AAKCP4431B2ZPDelhiActive04 Jul 2020
18AAKCP4431B1ZNAssamActive13 Aug 2019
24AAKCP4431B1ZUGujaratActive14 Aug 2019

To see the full GST registrations and return filing status of Panacea Biotec Pharma Limited, buy the company report.

Recent activity

Panacea Biotec Pharma Limited has 17 board changes on record since 2019: 6 appointments and 11 cessations. The latest: Sanjay Trehan was appointed as Whole-Time Director on 13 Feb 2025.

AGM
Panacea Biotec Pharma Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Filing
Panacea Biotec Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi.
Appointed
Sanjay Trehan was appointed as Whole-Time Director.
Ceased
Sanjay Trehan ceased to be Additional Director.
Ceased
Rajesh Jain ceased to be Additional Director.
Appointed
Rajesh Jain was appointed as Director.
Ceased
Ankesh Jain ceased to be Director.
Appointed
Narotam Kumar Juneja was appointed as Whole-Time Director.
Ceased
Narotam Kumar Juneja ceased to be Additional Director.
Charges
A charge registered on 01 Feb 2020 via Charge ID 100332250 with Others was fully satisfied on 03 Mar 2022.
Charges
A charge with Others of Rs. 754.44 Cr registered on 01 Feb 2020 with Charge ID 100332250 was modified on 16 Nov 2021.
Ceased
Manjula Upadhyay ceased to be Additional Director.

13 earlier events are in the company report.

Frequently asked questions

Panacea Biotec Pharma is an active public limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 22 March 2019 (7+ years old) and is registered under CIN U24299DL2019PLC347566.

Panacea Biotec Pharma has 6 current directors:

The latest financial statements of Panacea Biotec Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 29 September 2025. Year-wise statements from FY 2019 are in the company report.

The GSTIN of Panacea Biotec Pharma is 07AAKCP4431B1ZQ, registered in Delhi. The company has 22 GST registrations in all, of which 21 are active and 1 is cancelled or inactive. Other active GSTINs include 07AAKCP4431B2ZP (Delhi), 18AAKCP4431B1ZN (Assam), 24AAKCP4431B1ZU (Gujarat).

The CIN (Corporate Identification Number) of Panacea Biotec Pharma is U24299DL2019PLC347566. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Panacea Biotec Pharma has 5 court cases on record: 1 filed by the company and 4 filed against it. 2 are pending. Most are in the district courts.

Panacea Biotec Pharma was incorporated on 22 March 2019, making it 7+ years old. It is registered with the Registrar of Companies, Delhi.

Panacea Biotec Pharma has 3 deals on record (2 debt financings, 1 acquisition), with disclosed funding of ₹808.43 Cr; the latest was in February 2022.

The peers of Panacea Biotec Pharma by revenue are Amn Life Science Private Limited, Selmar Lab Private Limited, Psychotropics India Limited, all in the Healthcare industry (Formulations, Preventive Healthcare Supplements), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Sanjay Trehan was appointed as Whole-Time Director on 13 Feb 2025. Sanjay Trehan ceased to be Additional Director on 13 Feb 2025. Rajesh Jain ceased to be Additional Director on 05 Dec 2024. Panacea Biotec Pharma has 17 board changes on record in total.

Panacea Biotec Pharma has 34 MSME Form 1 returns on record between 2020 and 2024, listing 1,642 overdue payments to 181 micro and small suppliers. The latest return was filed on 29 Apr 2024.

Panacea Biotec Pharma can be reached through the website panaceabiotec.com. Its registered office is in New Delhi, Delhi, India.